{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:52:09Z","timestamp":1793919129079,"version":"4.8.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Analysis of the effect of finerenone on renal function in patients with type 2 diabetic nephropathy and its safety profile","award":["2024YW03"],"award-info":[{"award-number":["2024YW03"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study is aimed to systematically evaluate the efficacy and safety of Finerenone (BAY 94-8862) in the treatment of diabetic kidney disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Databases including PubMed, Embase, and Web of science were searched for randomized controlled trials that assessed Finerenone in patients with diabetic kidney disease and were published up to January 7, 2025. The quality evaluation of literatures and meta-analysis were performed using RevMan 5.4 software and independently operated by 2 experimenters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seven randomized controlled trials involving 33,455 patients were included. The efficacy outcomes were the ratio of urine albumin creatine ratio at posttreatment versus at baseline (mean difference: \u22120.30; 95% confidence interval [CI; \u22120.32, \u22120.27];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20050%), the primary composite outcome (hazard ratio [HR]: 0.81; 95% CI [0.76, 0.87];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200513%), the secondary composite outcome (HR: 0.82; 95% CI [0.74, 0.91];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0001;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20050%), kidney failure (HR: 0.76; 95% CI [0.70, 0.83];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20050%), and the risk of end stage kidney disease (HR: 0.87; 95% CI [0.77, 0.99];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.03;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200546%). The safety outcome was the incidence of adverse events (risk ratio: 1.00; 95% CI [0.99, 1.00];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.38;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20050%) and the number of patients suffering from hyperkalemia (risk ratio: 2.19; 95% CI [2.04, 2.34];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u20050%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Results of meta-analysis showed that Finerenone could significantly reduce urine albumin creatine ratio levels. It has a protective effect on kidney, delaying the progression of chronic kidney disease and reducing the risk of end stage kidney disease. Furthermore, there was no difference in the risk of overall adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047098","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:02:19Z","timestamp":1769191339000},"page":"e47098","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4030-5054","authenticated-orcid":false,"given":"Kai","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The First People\u2019s Hospital of Jiande, Hangzhou, Zhejiang Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First People\u2019s Hospital of Jiande, Hangzhou, Zhejiang Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First People\u2019s Hospital of Jiande, Hangzhou, Zhejiang Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260610","first-page":"608","article-title":"Mineralocorticoid receptor antagonist finerenone in DKD:From molecular structure to the cardio-renal protective mechanism.","volume":"40","author":"Lyu","year":"2024","journal-title":"Chin J Endocrinol Metab"},{"key":"R2-20260610","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/00325481.2024.2377529","article-title":"Clinical trial designs of emerging therapies for diabetic kidney disease (DKD).","volume":"136","author":"Singh","year":"2024","journal-title":"Postgrad Med"},{"key":"R3-20260610","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/dc21-1944","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD Study.","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"R4-20260610","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3390\/biom12091227","article-title":"Oxidative stress and NRF2\/KEAP1\/ARE pathway in Diabetic Kidney Disease (DKD): New Perspectives.","volume":"12","author":"Tanase","year":"2022","journal-title":"Biomolecules"},{"key":"R5-20260610","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1681\/ASN.2018060599","article-title":"LRG1 promotes diabetic kidney disease progression by enhancing TGF-\u03b2-induced angiogenesis.","volume":"30","author":"Hong","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R6-20260610","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives.","volume":"23","author":"Sawami","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"R7-20260610","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00059-022-05138-2","article-title":"Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes Lessons from the FIGARO-DKD trial.","volume":"47","author":"Haller","year":"2022","journal-title":"Herz"},{"key":"R8-20260610","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"R9-20260610","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes.","volume":"10","author":"Filippatos","year":"2022","journal-title":"Jacc-Heart Failure"},{"key":"R10-20260610","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/dom.15387","article-title":"Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.","volume":"26","author":"Eissing","year":"2024","journal-title":"Diabetes Obesity Metab"},{"key":"R11-20260610","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"J S. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"R12-20260610","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"key":"R13-20260610","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and Type 2 diabetes A FIDELITY subgroup analysis.","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"R14-20260610","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"R15-20260610","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial.","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"R16-20260610","first-page":"e43","article-title":"Cardiovascular events with finerenone in CKD and diabetes REPLY.","volume":"386","author":"Pitt","year":"2022","journal-title":"N Engl J Med"},{"key":"R17-20260610","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes.","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"R18-20260610","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40262-022-01124-3","article-title":"Dose-exposure-response analysis of the nonsteroidal mineralocorticoid receptor antagonist finerenone on UACR and eGFR: an analysis from FIDELIO-DKD.","volume":"61","author":"Goulooze","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R19-20260610","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3803\/EnM.2022.1629","article-title":"Renal protection of mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease.","volume":"38","author":"Kim","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R20-20260610","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","article-title":"Mineralocorticoid receptor antagonists: a comprehensive review of finerenone.","volume":"22","author":"Rico-Mesa","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"R21-20260610","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease.","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Pressure Res"},{"key":"R22-20260610","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s13300-023-01439-9","article-title":"Prevalence of diabetic kidney disease with different subtypes in hospitalized patients with diabetes and correlation between eGFR and LncRNA XIST expression in PBMCs.","volume":"14","author":"Lin","year":"2023","journal-title":"Diabetes Ther"},{"key":"R23-20260610","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial.","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"R24-20260610","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jdiacomp.2018.12.010","article-title":"The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease.","volume":"33","author":"Limkunakul","year":"2019","journal-title":"J Diabetes Complications"},{"key":"R25-20260610","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"R26-20260610","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial.","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:02:46Z","timestamp":1781085766000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047098","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-10-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}